Soligenix (SNGX) Given a $5.00 Price Target by Maxim Group Analysts

Maxim Group set a $5.00 price objective on Soligenix (NASDAQ:SNGX) in a research note published on Thursday. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright set a $3.00 price objective on shares of Soligenix and gave the company a hold rating in a research report on Friday, March 16th.

How to Become a New Pot Stock Millionaire

Shares of Soligenix stock opened at $1.92 on Thursday. The company has a market cap of $16.78, a price-to-earnings ratio of -1.85 and a beta of 0.46. Soligenix has a 52-week low of $1.74 and a 52-week high of $5.08.

COPYRIGHT VIOLATION WARNING: “Soligenix (SNGX) Given a $5.00 Price Target by Maxim Group Analysts” was first published by Ticker Report and is owned by of Ticker Report. If you are reading this story on another site, it was stolen and reposted in violation of U.S. & international copyright and trademark law. The legal version of this story can be viewed at https://www.tickerreport.com/banking-finance/3298889/soligenix-sngx-given-a-5-00-price-target-by-maxim-group-analysts-2.html.

About Soligenix

Soligenix, Inc, a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates through two segments, BioTherapeutics and Vaccines/BioDefense. The BioTherapeutics segment develops SGX301, a photodynamic therapy, which is in Phase III clinical trial to treat cutaneous T-cell lymphoma; and proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, including pediatric Crohn's disease and acute radiation enteritis.

Receive News & Ratings for Soligenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soligenix and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Pioneer Natural Resources to Post Q1 2018 Earnings of $1.54 Per Share, Piper Jaffray Forecasts
Pioneer Natural Resources to Post Q1 2018 Earnings of $1.54 Per Share, Piper Jaffray Forecasts
Novavax  Price Target Cut to $2.00
Novavax Price Target Cut to $2.00
Scorpio Tankers  Forecasted to Post Q1 2018 Earnings of  Per Share
Scorpio Tankers Forecasted to Post Q1 2018 Earnings of Per Share
PC Tel  Stock Rating Upgraded by Zacks Investment Research
PC Tel Stock Rating Upgraded by Zacks Investment Research
Zacks Investment Research Downgrades REGENXBIO  to Sell
Zacks Investment Research Downgrades REGENXBIO to Sell
HC Wainwright Reiterates “Buy” Rating for Synlogic
HC Wainwright Reiterates “Buy” Rating for Synlogic


© 2006-2018 Ticker Report. Google+.